Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Eur J Endocrinol. 2016 May 10;175(2):K1–K6. doi: 10.1530/EJE-16-0262

Figure 2. CYP11B2 immunohistochemistry and Sanger sequencing results of each tumor piece.

Figure 2

A. Low magnification scan of tumor pieces with CYP11B2 IHC (CYP11B2; brown). Scale bars, 5 mm. B. Results of Sanger sequencing of KCNJ5 gene (upper panel) and subsequent analysis of PCR product (lower panel). KCNJ5 gene mutations (p.T148I/T149S) were detected in B2T1, B2T2, and B2T3 but not in T1, T2, and T3. Subsequent analysis of PCR product (B2T3) showed both mutations were present in the same allele (clone A) and the other allele was wild type (clone B). C. Results of Sanger sequencing of PRKACA gene. PRKACA gene mutations (p.L206R) were identified in T1, T2, and T3 but not in B2T1, B2T2, and B2T3. IHC, immunohistochemistry; B2T1, CYP11B2 positive tumor specimen 1; B2T2, CYP11B2 positive tumor specimen 2; B2T3, CYP11B2 positive tumor specimen 3, T1, CYP11B2 negative tumor specimen 1; T2, CYP11B2 negative tumor specimen 2, T3, CYP11B2 negative tumor specimen 3.